August 2017 Br J Cardiol 2017;24:97
BJCardio Staff
A new gene therapy that targets the heart and requires only one treatment session, has been found safe for patients with coronary artery disease, according to a successful trial carried out in Finland (doi: 10.1093/eurheartj/ehx352). The treatment enhances circulation in ischaemic heart muscle and the effects were still visible one year after treatment. The randomised, blinded, placebo-controlled phase 1/2a trial was carried out in collaboration between the University of Eastern Finland, Kuopio University Hospital and Turku PET Centre. The biological bypass is based on gene transfer in which a natural human growth factor, AdVEGF-DΔNΔC, a ne
January 2008 Br J Cardiol 2008;15:7-11
BJCardio editorial team
Two phase I studies with anacetrapib (Lancet 2007;370:1907–14), show impressive effects on raising high-density lipoprotein cholesterol (HDL-C) and lowering low-density lipoprotein (LDL-C), with no signs of any increase in blood pressure. The authors, from Merck, US, conclude: “Anacetrapib seems to exhibit HDL-C increases greater than those seen with other investigational drugs in this class and LDL-C-lowering effects similar to statins. Despite greater lipid-altering effects relative to other members of this class, anacetrapib seems not to increase blood pressure, suggesting that potent CETP inhibition by itself might not lead to incre
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits